- Cathie Wood’s ARK Investment Management bought more Tempus shares this week, even as the stock hit a one-year low and the firm trimmed exposure across several large tech holdings.
- So far this year, ARKK and ARKG have poured nearly $28 million into Tempus shares.
- The buying followed expanding AI-driven oncology partnerships with Daiichi Sankyo, Merck, Blood Cancer United, NYU Langone Health and Northwestern Medicine.
Shares of Tempus AI Inc. (TEM) drew renewed attention this week after Cathie Wood’s ARK Investment Management added to its position while cutting stakes across several large tech firms, signaling continued conviction even as the stock hit a one-year low.
TEM stock fell nearly 3% on Thursday and is headed for its fifth straight weekly loss, shedding roughly 25% over the past five weeks.
Tempus Only Stock ARKK Bought In Latest Buy
On Thursday, ARK Investment Management purchased 51,881 shares through the ARK Innovation ETF (ARKK), worth $2.4 million based on Tempus’ closing price of $45.53. Notably, Tempus was the only stock ARKK bought in the session, even as the firm reduced exposure across several large tech holdings, including Alphabet, Baidu, Broadcom, Illumina, Archer Aviation, AMD, Nvidia and Meta.
The purchase followed additional accumulation a day earlier, when ARKK acquired 72,290 shares and the ARK Genomic Revolution ETF (ARKG) added 12,649 shares, worth $4 million.
Earlier in the quarter, ARK accumulated shares following Tempus’ earnings report and momentum from its partnerships. On Feb.25, ARKK bought 179,013 shares, while ARKG added 33,812 shares, implying purchases worth about $11.4 million.
The accumulation this year began on Feb.12, when ARKK purchased 174,585 shares and ARKG added 35,716 shares, representing roughly $10.7 million using Tempus’ $50.78 closing price. Cumulatively, ARK poured nearly $28 million into Tempus shares so far this year.
Tempus Expands Big Pharma AI Deals
ARK’s accumulation comes after Tempus expanded its role in precision oncology research and clinical-trial optimization pipelines. Most recently, Tempus partnered with Japanese pharma giant Daiichi Sankyo to develop a new cancer therapy, using its Prism2 AI model to better identify patients most likely to benefit from treatment.
Earlier this month, the company expanded its collaboration with Merck to support biomarker discovery across oncology and potentially broader therapeutic programs using its Lens platform and real-world datasets. Tempus also announced a deal with Blood Cancer United to build a registry focused on pediatric acute myeloid leukemia (AML).
The developments followed additional collaborations this year with Median Technologies, NYU Langone Health and Northwestern Medicine supporting genomic testing workflows, lung-cancer screening and molecular oncology programs.
Wall Street Sees Long-Term Upside For Tempus
Wall Street commentary this year reflected some price-target resets following quarterly results, but maintained confidence in Tempus’ long-term platform strategy. H.C. Wainwright raised its target to $95 and maintained a 'Buy' rating, while Baird lifted its target to $68 and reiterated an 'Outperform' rating. BTIG also maintained a 'Buy' rating, citing Tempus’s “first mover advantage on its large data business” and $1.1 billion backlog supporting expansion.
Meanwhile, JPMorgan lowered its price target to $60 and kept a 'Neutral' rating, citing “clouded visibility” around data-segment upside, while TD Cowen cut its target to $70 and maintained a 'Hold' rating. Mizuho initiated coverage with an 'Outperform' rating and a $100 target, calling precision oncology diagnostics a $40 billion market growing about 30% annually.
Tempus reported fourth-quarter revenue of $367.2 million, beating estimates, and projected fiscal-year 2026 revenue of about $1.59 billion, roughly in line with forecasts. CEO Eric Lefkofsky said that growth in diagnostics volumes and the company’s AI-driven data platform is expected to support expansion in the coming years.
What Do Retail Traders Feel About Tempus AI?
On Stocktwits, retail sentiment for TEM has been in the ‘bearish’ territory over the past week, slipping from ‘extremely bullish’ levels a month ago amid over a 90% surge in message volumes this quarter. Meanwhile, the stock has seen nearly a 50% jump in watchers over the past year.
One user expressed optimism, noting that “The only thing Cathie bought today was us here at Tempus.”
Another user said, “Experience told me that this is a good moment to buy, with what we can or what we have. Cathie is loading up, so, [why] don’t we? It will boom, someday, but success needs pain.”
TEM stock has declined 15% over the past year.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Read Next: Tesla Stock Fails To Catch Tailwind From Surging Gas Prices Ahead Of Crucial Q1 Delivery Report